Study Evaluating INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Inclusion Criteria:

1. Male or female patients aged ≥40 years based on the date of the written informedconsent form

2. Diagnosis of IPF as defined by American Thoracic Society/European RespiratorySociety/Japanese Respiratory Society/Latin American Thoracic Association guidelines

3. In a stable condition and suitable for study participation based on the results ofmedical history, physical examination, vital signs, 12-lead ECG, and laboratoryevaluation

4. Subjects with background pirfenidone or nintedanib may be enrolled if their regimenof antifibrotic therapy has been stable for > 8 weeks prior to Visit 1

5. Meeting all of the following criteria during the screening period:

6. FVC ≥40% predicted of normal

7. DLCO corrected for Hgb ≥25% and ≤80% predicted of normal.

8. forced expiratory volume in the first second/FVC (FEV1/FVC) ratio >0.7 based onpre-bronchodilator value

Exclusion Criteria:

1. Acute IPF exacerbation within 4 months prior to Visit 1 and/or during the screeningperiod, as determined by the investigator

2. Patients who are unwilling to refrain from smoking within 3 months prior toscreening and until the end of the study

3. Female patients who are pregnant or nursing

4. Abnormal ECG findings

Other protocol inclusion and exclusion criteria may apply.